Performance of 2-Deoxy-2-[F-18]fluoro-d-glucose Positron Emission Tomography and Integrated PET/CT in Restaged Breast Cancer Patients
- 1 September 2005
- journal article
- research article
- Published by Springer Nature in Molecular Imaging & Biology
- Vol. 7 (5) , 369-376
- https://doi.org/10.1007/s11307-005-0013-4
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Osteocyte density in woven boneBone, 2004
- Advantages and limitations of FDG PET in the follow-up of breast cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2004
- Prospective Multicenter Study of Axillary Nodal Staging by Positron Emission Tomography in Breast Cancer: A Report of the Staging Breast Cancer With PET Study GroupJournal of Clinical Oncology, 2004
- Staging of Non–Small-Cell Lung Cancer with Integrated Positron-Emission Tomography and Computed TomographyNew England Journal of Medicine, 2003
- F-18 Fluorodeoxyglucose Positron-Emission Tomography in the Diagnosis of Tumor Recurrence and Metastases in the Follow-Up of Patients With Breast CarcinomaInvestigative Radiology, 2003
- Determinants of Diagnostic Performance Of [F-18]Fluorodeoxyglucose Positron Emission Tomography for Axillary Staging in Breast CancerAnnals of Surgery, 2002
- Comparing whole body 18 F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancerZeitschrift für Krebsforschung und Klinische Onkologie, 2002
- The role of zoledronic acid in cancer: Clinical studies in the treatment and prevention of bone metastasesSeminars in Oncology, 2001
- Pitfalls in Oncologic Diagnosis with FDG PET Imaging: Physiologic and Benign VariantsRadioGraphics, 1999
- Attenuation correction for a combined 3D PET/CT scannerMedical Physics, 1998